H107e/CAF10b
Candidate Overview
H107e/CAF®10b is being developed by SSI and is a next-generation TB subunit vaccine incorporating 8 different Mtb antigens in a novel liposomal Th1/Th17 inducing adjuvant. It is specifically designed to complement a BCG response with novel T cells against Mtb-specific antigens and comes with the option of BCG co-administration.
Sponsor / Lead Developer: Statens Serum Institut
Clinical Trial Status: Active Trials
Primary Indication: Prevention of TB disease
Target Population(s): Adolescents, Adults, Infants, People living with HIV, People with Mtb infection, and People without Mtb infection
Target Route of Administration: Intramuscular
Clinical Trials
ACTIVE TRIALS |
|
| Registry Number | NCT06050356 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | Statens Serum Institute |
| Primary endpoint(s) for this clinical trial | Safety |
| Immunogenicity | |
| Target population(s) for clinical trial | Adults |
| People with Mtb infection | |
| People without Mtb infection | |
Related Publications
Trial-specific publications are listed above with the clinical trial listing
- MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates (Nat Commun, 2024)
- A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG. (NPJ Vaccines, 2023)
- A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. (Nat Commun., 2021)